Mumbai: The proposed draft pharma policy is likely to impact those multinational companies the most, which are in the premium pricing band, say analysts.
The new pricing policy finalised by the group of ministers last week will take the number of essential drugs under price control regime to as many as 348.
At present, the prices of 74 bulk drugs and their formulations are controlled.
"We acknowledge the rights of the government to make essential medicines available to the most vulnerable sections of society at affordable prices. The new proposal will have an impact on industry as the span of price controls will now increase to cover around 30 percent of the pharma market.
Still a market-based policy is a balanced formula and will help improve the availability of essential medicines for patients," Organisation of Pharmaceutical Producers of India (OPPI) president and Novartis India vice-chairman and managing director Ranjit Shahani told PTI here.
The GoM had recommended that the retail price of essential 348 drugs will be fixed at weighted average price of brands that have more than 1 percent market share.
The proposed policy will cover 30 percent of the industry and will bring down the average prices by about 10 percent.
"The companies, which are in the premium pricing band would be impacted the most. MNCs in particular, which have a pure domestic play like GSK Pharma and Sanofi India would be impacted the most, resulting in a profit contraction of the entire business," Karvy analyst Nishith Sanghvi said in a note.
The domestic companies not having very huge exposure to the domestic market, will be insulated to some extent, but they will see some contraction in their margins from the domestic segment, impacting the profitability, Sanghvi said.
Companies such as Reddy's, Sun Pharma, Lupin, Ranbaxy and Cipla would be less affected due to their presence in the exports space, he added.